Skip Header

 
Contribute Send feedback

Reviewed, UniProtKB/Swiss-Prot P06239 (LCK_HUMAN)

Last modified September 2, 2008. Version 130. Feed History...

Clusters with 100%, 90%, 50% identity | Documents (8) | Third-party data | Customize display text xml rdf/xml gff fasta
Names and origin · Protein attributes · General annotation (Comments) · Ontologies · Binary interactions · Alternative products · Sequence annotation (Features) · Sequences · References · Web resources · Cross-references · Entry information · Relevant documents

Names and origin

Protein namesRecommended name:
    Proto-oncogene tyrosine-protein kinase LCK
    EC=2.7.10.2
Alternative name(s):
    Lymphocyte cell-specific protein-tyrosine kinase
    p56-LCK
    LSK
    T cell-specific protein-tyrosine kinase
Gene names
Name: LCK
OrganismHomo sapiens (Human)
Taxonomic identifier9606 [NCBI]
Taxonomic lineageEukaryotaMetazoaChordataCraniataVertebrataEuteleostomiMammaliaEutheriaEuarchontogliresPrimatesHaplorrhiniCatarrhiniHominidaeHomo

Protein attributes

Sequence length509 AA.
Sequence statusComplete.
Sequence processingThe displayed sequence is further processed into a mature form.
Protein existenceEvidence at protein level.

General annotation (Comments)

Function

Tyrosine kinase that plays an essential role for the selection and maturation of developing T-cell in the thymus and in mature T-cell function. Is constitutively associated with the cytoplasmic portions of the CD4 and CD8 surface receptors and plays a key role in T-cell antigen receptor(TCR)-linked signal transduction pathways. Association of the TCR with a peptide antigen-bound MHC complex facilitates the interaction of CD4 and CD8 with MHC class II and class I molecules, respectively, and thereby recruits the associated LCK to the vicinity of the TCR/CD3 complex. LCK then phosphorylates tyrosines residues within the immunoreceptor tyrosines-based activation motifs (ITAMs) in the cytoplasmic tails of the TCRgamma chains and CD3 subunits, initiating the TCR/CD3 signaling pathway. In addition, contributes to signaling by other receptor molecules. Associates directly with the cytoplasmic tail of CD2, and upon engagement of the CD2 molecule, LCK undergoes hyperphosphorylation and activation. Also plays a role in the IL2 receptor-linked signaling pathway that controls T-cell proliferative response. Binding of IL2 to its receptor results in increased activity of LCK. Is expressed at all stages of thymocyte development and is required for the regulation of maturation events that are governed by both pre-TCR and mature alpha beta TCR.

Catalytic activity

ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate.

Enzyme regulation

Inhibited by tyrosine phosphorylation.

Subunit structure

Binds to the cytoplasmic domain of cell surface receptors, such as CD2, CD4, CD5, CD8, CD44, CD45 and CD122. Also binds to effector molecules, such as PI4K, VAV1, RASA1, FYB and to other protein kinases including CDC2, RAF1, ZAP70 and SYK. Binds to phosphatidylinositol 3'-kinase (PI3K) from T-lymphocytes through its SH3 domain and to the tyrosine phosphorylated form of KHDRBS1/p70 through its SH2 domain. Binds to HIV-1 Nef through its SH3 domain. This interaction inhibits its tyrosine-kinase activity. Interacts with SQSTM1. Interacts with phosphorylated LIME1. Interacts with CBLB and PTPRH.

Subcellular location

Cytoplasm. Cell membrane; Lipid-anchor; Cytoplasmic side. Note= Present in lipid rafts in an unactive form.

Tissue specificity

Expressed specifically in lymphoid cells.

Domain

The SH2 domain mediates interaction with SQSTM1. Interaction is regulated by Ser-59 phosphorylation.

Post-translational modification

Phosphorylated on Tyr-394, which increases enzymatic activity By similarity. Phosphorylated on Tyr-505, which decreases activity.

Involvement in disease

A chromosomal aberration involving LCK is found in leukemias. Translocation t(1;7)(p34;q34) with TCRB.

Sequence similarities

Belongs to the protein kinase superfamily. Tyr protein kinase family. SRC subfamily.

Contains 1 protein kinase domain.

Contains 1 SH2 domain.

Contains 1 SH3 domain.

Mass spectrometry

Molecular weight is 57869.42 Da from positions 2 - 509. Determined by MALDI. Ref.20

Ontologies

Keywords

   Biological processHost-virus interaction
   Cellular componentCell membrane
Cytoplasm
Membrane
   Coding sequence diversityAlternative splicing
Chromosomal rearrangement
   DiseaseDisease mutation
Proto-oncogene
   DomainSH2 domain
SH3 domain
   LigandATP-binding
Nucleotide-binding
   Molecular functionKinase
Transferase
Tyrosine-protein kinase
   PTMLipoprotein
Myristate
Palmitate
Phosphoprotein
   Technical term3D-structure

Gene Ontology (GO)

   Biological processRas protein signal transduction

Traceable author statement. Source: ProtInc

T cell differentiation

Inferred from mutant phenotype. Source: UniProtKB

caspase activation

Inferred from direct assay. Source: UniProtKB

cellular zinc ion homeostasis

Inferred from expression pattern. Source: UniProtKB

induction of apoptosis

Inferred from mutant phenotype. Source: UniProtKB

positive regulation of T cell activation

Inferred from direct assay. Source: UniProtKB

positive regulation of T cell receptor signaling pathway

Non-traceable author statement. Source: UniProtKB

protein amino acid phosphorylation Ref.2

Traceable author statement. Source: ProtInc

release of sequestered calcium ion into cytosol

Inferred from sequence or structural similarity. Source: UniProtKB

response to drug

Inferred from direct assay. Source: UniProtKB

   Cellular componentcytosol

Inferred from Experiment. Source: Reactome

membrane raft

Inferred from direct assay. Source: UniProtKB

pericentriolar material

Inferred from direct assay. Source: UniProtKB

plasma membrane

Non-traceable author statement. Source: UniProtKB

   Molecular functionATPase binding

Inferred from physical interaction. Source: UniProtKB

CD4 receptor binding

Inferred from physical interaction. Source: UniProtKB

CD8 receptor binding

Inferred from physical interaction. Source: UniProtKB

SH2 domain binding Ref.15 Ref.17

Inferred from physical interaction. Source: UniProtKB

glycoprotein binding

Inferred from physical interaction. Source: UniProtKB

phosphoinositide 3-kinase binding Ref.14

Inferred from physical interaction. Source: UniProtKB

protein C-terminus binding

Inferred from physical interaction. Source: UniProtKB

protein kinase binding Ref.16

Inferred from physical interaction. Source: UniProtKB

protein serine/threonine phosphatase activity

Inferred from direct assay. Source: UniProtKB

protein tyrosine kinase activity Ref.4

Inferred from direct assay. Source: UniProtKB

Complete GO annotation...

Alternative products

This entry describes 3 isoforms produced by alternative splicing. [Align] [Select]
Isoform Long (identifier: P06239-1)

This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry.
Isoform Short (identifier: P06239-2)

The sequence of this isoform differs from the canonical sequence as follows:
     348-363: IAEGMAFIEERNYIHR → VRRLGRGAGQGNRPVT
     364-509: Missing.
Notes: No experimental confirmation available.
Isoform 3 (identifier: P06239-3)

The sequence of this isoform differs from the canonical sequence as follows:
     321-321: N → NDTLLDSQLEEKGLGASPWGNLGQQLLLLPT
Notes: No experimental confirmation available.

Sequence annotation (Features)

Feature keyPosition(s)LengthDescriptionGraphical view

Molecule processing

Initiator methionine11Removed Probable
Chain2 – 509508Proto-oncogene tyrosine-protein kinase LCK

Regions

Domain61 – 12161SH3
Domain127 – 22498SH2
Domain245 – 498254Protein kinase
Nucleotide binding251 – 2599ATP By similarity
Region2 – 7271Interactions with CD4 and CD8 By similarity
Region154 – 24289Interaction with PTPRH

Sites

Active site3641Proton acceptor By similarity
Binding site2731ATP By similarity

Amino acid modifications

Modified residue1621Phosphoserine
Modified residue1921Phosphotyrosine
Modified residue2131Phosphoserine
Modified residue3941Phosphotyrosine; by autocatalysis
Modified residue5011Phosphothreonine
Modified residue5051Phosphotyrosine
Lipidation21N-myristoyl glycine By similarity
Lipidation31S-palmitoyl cysteine By similarity
Lipidation51S-palmitoyl cysteine By similarity

Natural variations

Alternative sequence3211N → NDTLLDSQLEEKGLGASPWG NLGQQLLLLPT in isoform 3.
Alternative sequence348 – 36316IAEGM…NYIHR → VRRLGRGAGQGNRPVT in isoform Short.
Alternative sequence364 – 509146Missing in isoform Short.
Natural variant281V → L in leukemia.
Natural variant2321P → PQKP in leukemia.
Natural variant3531A → V in leukemia.
Natural variant4471P → L in leukemia.

Experimental info

Mutagenesis591S → E: Allows interaction with SQSTM1
Mutagenesis1541R → K: No effect on interaction with SQSTM1
Sequence conflict291P → R in AAA59502. Ref.2
Sequence conflict351T → R in AAA59502. Ref.2
Sequence conflict871Q → P in CAA31884 and AAA59502. Ref.2
Sequence conflict206 – 2116VRHYTN → ASAITPI in CAA28691. Ref.1
Sequence conflict2541G → A in AAA59502. Ref.2
Sequence conflict258 – 26710EVWMGYYNGH → RCGWGTTTGT in CAA28691. Ref.1
Sequence conflict282 – 2865PDAFL → AGRLP in CAA28691. Ref.1
Sequence conflict3751T → A Ref.12
Sequence conflict4721L → H Ref.11
Sequence conflict504 – 5096QYQPQP → STA in CAA28691. Ref.1

Secondary structure

................................................................................ 509
Helix Strand Turn

Details...